The combination of the monoclonal antibodies bevacizumab and atezolizumab, targeting vascular endothelial growth factor (VEGF)-A and PD-L1, respectively, has become the standard of treatment for advanced HCC settings [6]. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.